Immune-Related Adverse Events after Immune Checkpoint Blockade-Based Therapy are Associated with Improved Survival in Advanced Sarcoma

1st irAE - Type of first immune-related adverse event (irAE) of any grade (phv00530701.v1.p1)
2nd irAE - Type of second immune-related adverse event (irAE) of any grade (phv00530702.v1.p1)
ANALYTE_TYPE - Analyte type (phv00530706.v2.p1)
BODY_SITE - Body site of origin of sample (phv00530705.v2.p1)
CONSENT - Consent group as determined by DAC (phv00530692.v1.p1)
Grade >= 3 irAE - Type of immune-related adverse event (irAE) of grade three or higher (phv00530703.v1.p1)
HISTOLOGICAL_SUBTYPE - Tissue subtype of sample (phv00530709.v2.p1)
HISTOLOGICAL_TYPE - Tissue type of sample (phv00530708.v2.p1)
IS_TUMOR - Tumor status (phv00530707.v2.p1)
PAIRED_SAMPLE - Sample ID of paired tissue collected from the same patient at a different timepoint, if applicable (phv00544316.v1.p1)
SAMPLE_ID - Sample ID (phv00530704.v2.p1)
SAMPLE_ID - Sample ID (phv00530697.v2.p1)
SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00530695.v1.p1)
SUBJECT_ID - Subject ID (phv00530698.v1.p1)
SUBJECT_ID - Subject ID (phv00530691.v1.p1)
SUBJECT_ID - Subject ID (phv00530696.v2.p1)
SUBJECT_SOURCE - Source repository where subjects originate (phv00530694.v1.p1)
TIMEPOINT - Timepoint of sample collection (phv00544315.v1.p1)
Trial - Clinical trial (phv00530700.v1.p1)